|Description||ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas. It is still under preclinical trials in Colorectal cancer. IC50: 3.8|
|Synonyms||UNII-QJ8RO3296G; QJ8RO3296G; CHEMBL3115681; ON123300; SCHEMBL10050883; BDBM50447512|
|Solubility||10 mM in DMSO|
|Application||ON123300 has been found to be an effective multikinase inhibitor that could be probably used against brain tumor and mantle cell lymphomas.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
|Current Developer||Icahn School of Medicine at Mount Sinai; Onconova Therapeutics|
Abemaciclib is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potentia...
TG003 is a potent, ATP-competitive inhibitor of Clk-family kinases. TG003 inhibited SF2/ASF-dependent splicing of beta-globin pre-mRNA in vitro by suppression o...
CDK-IN-2 is a potent and sepecific CDK inhibitor.
Bohemine, structurally similar to Olomoucine and Roscovitine, is a 2,6,9-trisubstituted purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhi...
SU 9516 is a potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively...
Senexin A is a selective Cell division protein kinase 8 (CDK8) inhibitor with IC50 value of 280 nM. Senexin A can bind to cdk19 in an ATP-competitive manner and...
CGP74514A is a cell permeable Cdk inhibitor selective for Cyclin-dependent kinase-1 (Cdk1) (IC50=25nM). CGP74514A was also reported also to affect the activitie...
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a ribonucleotide reductase inhibitor and iron chelator with anti-tumor activity.
Ca2+ Channel Agonist 1
A Ca2+ Channel Agonist that selectively acting on N-type Ca2+ channel and also be found to restrain the cdk activity at some extent. IC50: 14.23 uM (EC50, Ca2+ ...
AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an eff...
Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by p...
AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.
RO-3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO-3306 induced G2/M-phase cell cycle arrest and apoptosis ...
Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...
LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...
Riviciclib, also known as P276-00, is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 selectively binds to and ...
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...
LEE011 succinate hydrate
LEE011 succinate hydrate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with pot...
CGP-79807 is a potent CDC2 protein kinase inhibitor that originated by Novartis. In Sep 2000, Preclinical development for Cancer in Switzerland was on-going, bu...